Therapy Areas: Inflammatory Diseases
LabGenius and Sanofi launch AI-driven collaboration on antibody optimisation
4 December 2025 - Drug discovery company LabGenius Therapeutics announced on Thursday a new collaboration with French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) to optimise thera...
Mitsubishi Tanabe Pharma America changes name
2 December 2025 - Mitsubishi Tanabe Pharma America Inc (MTPA), a subsidiary of Japan-based Mitsubishi Tanabe Pharma Corporation (MTPC), announced on Monday that it has changed its corporate name to Ta...
Sanofi and Regeneron's Dupixent approved in EU for chronic spontaneous urticaria
25 November 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Tuesday that the European Commission has approved Dupixent (dupilumab) for adults and adolescent...
Xenogenic Materials Demonstrate Promising Results in Peri-Implantitis Management
...
European Commission approves Insmed's BRINSUPRI for the treatment of non-cystic fibrosis bronchiectasis
18 November 2025 - US-based biopharmaceutical company Insmed Incorporated (Nasdaq: INSM) said on Tuesday that the European Commission has approved BRINSUPRI (brensocatib 25mg tablets) for patients wit...
European Commission approves Celltrion's Remsima IV liquid formulation
18 November 2025 - South Korea-based biopharmaceutical company Celltrion Inc (KRX:068270) announced on Tuesday that the European Commission has granted marketing authorisation for Remsima IV liquid fo...